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Enhanced surveillance of hepatitis B infection
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Abstract: Objectives: We developed an enhanced
surveillance system for hepatitis B to improve the
detection of newly acquired cases and to collect
epidemiological data. Methods: The study was
undertaken from February to June (inclusive) 2005
at the Sydney South West Area Health Service
Eastern Zone Public Health Unit. A letter was sent
to treating doctors on receipt of a notification,
requesting additional information on cases. Cases
identified by the treating doctors as newly
acquired were followed up by telephone. Results:
There were 295 notifications of hepatitis B in the
period, of which three were newly acquired infections. Only one of these three cases was identified
through enhanced surveillance. Information
on ethnicity was obtained. Conclusions: This
enhanced surveillance system is of limited value as
an ongoing process. We recommend that it be
undertaken periodically to monitor the epidemiology of the disease.

Hepatitis B is a viral infection that can cause chronic
inflammation of the liver and may lead to cirrhosis and
hepatocellular carcinoma.1 In Australia in 2005, 6793
unspecified hepatitis B notifications were reported to the
National Notifiable Disease Surveillance System, with
235 of these reported as being incident (or newly acquired)
cases.2 In NSW, there were 54 newly acquired cases
reported.2 Furthermore, it has been estimated that the
prevalence of chronic hepatitis B infection in Australia
ranges from 0.47–0.87%.3 Hepatitis B is preventable by
vaccination, and further spread can be avoided through
administration of immunoglobulin prophylaxis within
14 days of exposure,1 as well as through the provision of
information about modes of transmission and infection
control. In addition, new treatment modalities are proving
to be effective.4 It would therefore be beneficial for cases
10.1071/NB07058

of newly acquired hepatitis B to be detected in a timely
manner to allow effective public health action to be instituted, as well as to facilitate early referral for management.
Identifying newly acquired cases of hepatitis B can be
problematic, however, as laboratories usually only test and
report results for positive surface antigen (HBsAg), which
indicates unspecified infection with hepatitis B, rather
than IgM antibody to core antigen (HBcAb IgM), which
indicates newly acquired infection. In addition, clinical
details or related results such as liver function tests are
very rarely provided to the Public Health Unit (PHU).
Identification of newly acquired cases is therefore highly
dependent on the treating doctor notifying the PHU. While
medical practitioners are required under the NSW Public
Health Act 1991 to notify acute episodes of viral hepatitis,
it is acknowledged that under-reporting is a significant
issue.5,6 In addition, laboratories provide limited demographic data (age, sex and postcode only), resulting in an
incomplete picture of the epidemiology of hepatitis B.
A recent report of an enhanced surveillance system for
hepatitis B in south-eastern Sydney stated that it was
effective in increasing the detection of newly acquired
cases by three-fold (from three to 10 cases) over a sixmonth period.7 However, this system required a reasonably
high staff workload and relied on access to supplementary
investigation results and clinical details. Consequently, it
was unsuitable for implementation at our centre. An alternative enhanced surveillance system for hepatitis B infection was therefore developed, with the aims of improving
both the detection of newly acquired cases and the collection of epidemiological data to inform targeted public
health action. This article presents the results of this
enhanced surveillance and discusses the implications of its
implementation.

Methods
In NSW, hepatitis B infection is notifiable by laboratories
and acute viral hepatitis is notifiable by medical practitioners and hospitals under the Public Health Act 1991.
The case definition for newly acquired hepatitis B is provided in Box 1.8
Enhanced surveillance was undertaken from February to
June (inclusive) 2005 at the Sydney South West Area
Health Service (SSWAHS) Eastern Zone PHU, which
services a large, ethnically diverse population of approximately 500000 in inner-western Sydney.9 After receipt of
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Box 1. Case definition for newly acquired hepatitis B
infection8
• Detection of HBsAg in a patient shown to be negative
within the last 24 months, or
• Detection of HBsAg and IgM to hepatitis B core antigen,
in the absence of prior evidence of HBV infection, or
• Detection of HBV by nucleic acid testing, and IgM to
hepatitis B core antigen, in the absence of prior evidence
of HBV infection.
Source: Notifiable Diseases Manual, NSW Department of Health
2004

a laboratory notification of HBsAg, a letter and two-page
questionnaire were mailed to the medical practitioner who
requested the test. Due to limited human resources, a
reminder letter was not sent to treating doctors who did not
respond. The letter outlined the reasons for undertaking
this enhanced surveillance. The first page of the questionnaire requested demographic details of the case (gender,
occupation, country of birth, language spoken at home,
and Aboriginal and Torres Strait Islander status), and after
providing the case definition of a newly acquired case of
hepatitis B, it requested the practitioner’s opinion as to
whether this case of hepatitis B was newly acquired. In
addition, information regarding household or sexual contacts and the use of hepatitis B vaccine for these contacts
was requested, as well as asking if the medical practitioner
required further information regarding hepatitis B, either
for their patients or to assist with tertiary referrals.
If the case was considered newly acquired, the medical
practitioner was asked to complete the second page of the
questionnaire. This requested information regarding the
presence and onset date of symptoms, and possible risk
exposures. If further information was required for public
health follow-up, it was obtained by telephoning the
medical practitioner and the patient.
Data from returned questionnaires were entered into the
NSW Health Notifiable Diseases Database and into a separate database created in Microsoft Excel 2000, and frequencies of selected characteristics were calculated.
In addition to the laboratory notifications of HBsAg, the
PHU also received telephone notifications of acute hepatitis B directly from medical practitioners. The surveillance officers then obtained demographic and risk factor
information regarding these cases from the medical practitioner and, if permission was given, directly from the
patient. These cases were considered to be the ‘baseline’
number of notifications that would occur if the enhanced
surveillance system was not in place.
The cost to the PHU of implementing this enhanced surveillance system was calculated by recording the amount
of staff time taken for data entry, questionnaire and letter
116
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preparation and mail out, and telephone follow-up with
treating doctors.

Results
Enhanced surveillance
There were 295 notifications of hepatitis B in the period
February to July 2005 (average monthly notification rate
of 9.9 per 100000 people). Median time taken to send
questionnaires to treating doctors was 11 days from receipt
of the laboratory notification (range 1–36 days). Three
notifications were confirmed cases of newly acquired hepatitis B. Two of these were notified directly to the PHU by
the treating medical practitioner, and the remaining case
was detected as a result of the enhanced surveillance.
There were eight additional cases that medical practitioners indicated on the questionnaire were newly acquired,
but after follow-up by telephone it was determined that
these cases did not meet the case definition for a newly
acquired case. Out of the 293 laboratory notifications,
204 questionnaires were returned (response rate 69.6%).
There were 104 cases (51%) that had household contacts.
Of these cases, it was indicated by medical practitioners
that for 67 (64.4%), hepatitis B vaccination had been instituted for their contacts.
Less than a quarter of medical practitioners requested
further information regarding hepatitis B, either for the
information of their patients (n = 48, 23.1%) or to assist in
tertiary referral (n = 43, 21.1%).
The additional staff time that this enhanced surveillance
required was estimated to be four hours per week. If a
public health nurse (5th year) were employed to perform
these duties, the additional cost to the PHU would be
approximately $85 per week, or $4500 per year.10 If,
however, an existing public health surveillance officer
were used to carry out this surveillance, this would likely
be at the expense of an alternative communicable disease
control activity.
Demographics of cases
The demographic characteristics of these cases are shown
in Table 1 and country of birth data are shown in Figure 1.
Cases were predominantly male (56%) and aged 20–40
years. The majority of cases notified to the PHU spoke a
language other than English at home (66%) with 31%
speaking a Chinese dialect. Cases also tended to be born
overseas, primarily in China (28%) and Vietnam (21%).
In all three cases of newly acquired hepatitis B, risk
exposures were both unprotected sexual contact and
intravenous drug use. These three people were all born in
Australia, two were male and all were aged less than
30 years.

Enhanced surveillance of hepatitis B infection

Table 1. Demographic characteristics of people notified
with hepatitis B, Sydney South West Area Health Service
(Eastern Zone), NSW, February to July 2005 (n = 204)
Characteristic
Gender

Male
Female
Unknown
Median
Range

Age (years)
Language other than
English spoken at home

n

%

114
89
1
35
7–90
134

55.9
43.6
0.5

65.7

Demographics of catchment population
In the 2001 census, 50.6% of the PHU catchment population were male. The area is culturally diverse, with almost
40% of residents born overseas. The most common overseas countries of birth were China (4.2%), the UK (3.5%),
Italy (2.9%), Greece (2.6%) and Lebanon (2.3%).9

Discussion
This enhanced surveillance system was able to increase
the detection of cases of newly acquired hepatitis B over a
six-month period by one case. It also provided additional
information regarding ethnicity that would otherwise not
be available. In addition, it was helpful in obtaining some
(albeit limited) data regarding the needs of medical practitioners with respect to information regarding hepatitis B,
and the extent to which medical practitioners undertake
appropriate management of contacts.
Our results differ from those of a recently reported
enhanced surveillance system.7 This may be due to several
reasons. We did not have access to the results of supple-

Europe
4%

Indian subcontinent
2%

Middle East
2%
Africa
2%

Australia
8%
Pacific Islands
3%

Unknown
12%

South-east Asia
67%

Figure 1. Country of birth of people notified with hepatitis B
infection, Sydney South West Area Health Service (Eastern
Zone), NSW, February to July 2005 (n = 204)

mentary laboratory investigation or clinical details and
were therefore unable to predict case classification before
contacting treating doctors. This is unlikely to have made
a difference to our results, demonstrated by the relatively
large numbers of ‘false positive’ cases. It is possible that
the treating doctors in our PHU catchment area do not
under-report newly acquired cases of hepatitis B as is
widely believed, and therefore enhanced surveillance for
this reason is less important.
The inner-western region of Sydney has one of the highest
notification rates of hepatitis B in NSW, which has been
attributed to the large numbers of residents born in countries where hepatitis B is endemic.11 This is reflected in
these results, where, compared with the demographic
profile of the catchment population, a disproportionately
high number of people notified with hepatitis B were born
overseas, particularly in South-east Asia where hepatitis B
carriage rates have been estimated to be up to 20%.12
Vaccination of household contacts of people with hepatitis
B infection is known to reduce the risk of spread.1
Vaccination had been commenced in almost two-thirds of
cases with household contacts, moderately lower than
levels found in a previous study in northern Sydney
(88%),13 but greater than studies in the United Kingdom
(38%)14 and the United States (55%).15 Had there been
more time between receipt of laboratory notification and
mailing out of enhanced surveillance questionnaires, this
vaccination rate may have been even higher. There could
be other reasons for non-vaccination, however, such as
previous vaccination, contraindication to vaccine, the
failure of the contact to attend for vaccination, or the attendance of the contact to another provider for vaccination.
This information was not collected by this enhanced
surveillance, but it would be possible to do so in the future
to enable a better understanding of reasons for the nonvaccination of contacts.
Despite the good response rate (which is likely to have
been higher if additional human resources were available
to send reminder letters to non-responding treating
doctors), only one additional case of newly acquired hepatitis B was detected using this enhanced surveillance
system, which did enable public health follow-up that
would otherwise not have occurred. This was at the cost,
however, of additional staff time spent in following up
eight other cases that turned out to be ‘false positives’. In
addition, demographic information including ethnicity
and Aboriginality could be collected on all cases of hepatitis B, which assists in the understanding of the epidemiology of this disease, and could be used, in combination
with other methods, to estimate the prevalence of hepatitis
B.3 In the current climate of competing health funds, these
benefits need to be weighed against the costs of such a
surveillance system (including the time required by the
Vol. 18(7–8) NSW Public Health Bulletin
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treating doctors to complete the questionnaire). We would
recommend that an option is to periodically undertake
enhanced surveillance for a limited time, for example,
six to 12 months every two to three years, to monitor the
epidemiology of this disease. This would assist in filling
the gap in data on the prevalence and incidence of this significant public health problem and contribute to informed
public health practice.
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